

November 2, 2016
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting

TOKYO, Japan, November 2, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova") announced on November 1, 2017 (EST) that the following two abstracts relating to rigosertib were accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, which takes place December 9-12, 2017.

Abstract 1

"Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study"

LR-MDS patients currently have limited treatment options, and a large number are transfusion dependent, and some require red blood cell transfusions over an extended period. This study details achievements of oral rigosertib treatment with respect to TI and TR, and safety.

Abstract 2

"Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome"

The evaluation of rigosertib alone or in combination therapy on epigenetic reprogramming using CD34+ cells of patients indicates that epigenetic effects of rigosertib may lead to improved hematopoietic function and response in the clinical setting.

See the press release issued by Onconova at:

<http://investor.onconova.com/releases.cfm>

About myelodysplastic syndromes (MDS)

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). The number of MDS cases are expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk and higher-risk MDS. The number of drug-treated MDS patients is estimated to be about 7,700 in Japan (CancerMPact 2016).

About rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of Ras as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells.

SymBio obtained the development and commercialization licensing rights for rigosertib from Onconova in July, 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds are in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.